The mission of the Rutgers Cancer Institute of New Jersey (CINJ) is to reduce the burden of cancer by advancing cancer research, prevention, screening, education and care for one of the nation?s most diverse and densely populated states, as well as the broader nation. To accomplish this mission, the CINJ Director, Steven K. Libutti, MD, works closely with the rest of the CINJ Senior Leadership team, which includes the Deputy Director (Eileen White), and Associate Directors for Clinical Research (Howard S. Hochster), Basic Research (Eileen White), Cancer Prevention, Control and Population Research (Sharon L. Manne), Translational Research (Shridar Ganesan), Consortium Research (Yibin Kang), Research and Education Affairs (Edmund C. Lattime), Administration and Planning (Linda L. Tanzer) and Community Outreach and Engagement (new, Manne interim). Implementation of a five-year Strategic Plan (2015-2020) was underway at the time of Libutti?s arrival in 2017; the plan was re-assessed modified to represent the new Director?s vision. The Internal Advisory Board (includes the Chancellor, Deans and other leaders at Rutgers and Princeton Universities) and the External Advisory Board reviewed these proposed modifications and provided critical input and guidance. This oversight and leadership structure proved its effectiveness with the transition to a new Director; the major goals of the strategic plan were affirmed, with significant and sustained progress made toward accomplishing them, and new initiatives important to the Director?s vision were seamlessly integrated. Despite the change in Directorship, senior leaders did not lose momentum and achieved important strategic accomplishments, including: restructured and enhanced precision medicine initiative; recruitment of a new Associate Director for Clinical Research; increased accruals to interventional studies; creation of an Office of Community Outreach and Engagement and launch of a search for an Associate Director to oversee these efforts; expansion of the Metabolomics shared resource (jointly managed with Princeton University) and launch of two new developing shared resources for Small Molecule Screening (with Princeton) and Immune Monitoring; expansion of educational programs and successful management of major statewide retreats and conferences; launch of a new colon and lung cancer screening initiative for underserved regions of CINJ?s catchment area; and enhancement and strengthening of the consortium with Princeton University through the creation and appointment of an Associate Director for Consortium Research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA072720-22
Application #
10112886
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-03-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
22
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Patrizii, Michele; Bartucci, Monica; Pine, Sharon R et al. (2018) Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol 8:23
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
CeliĆ -Terrassa, Toni; Bastian, Caleb; Liu, Daniel et al. (2018) Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nat Commun 9:5005
Zloza, Andrew (2018) Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer. J Immunother Cancer 6:3
Paratala, Bhavna S; Chung, Jon H; Williams, Casey B et al. (2018) RET rearrangements are actionable alterations in breast cancer. Nat Commun 9:4821
George, Blessy; Joy, Melanie S; Aleksunes, Lauren M (2018) Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Exp Biol Med (Maywood) 243:272-282
Moloughney, Joseph G; Vega-Cotto, Nicole M; Liu, Sharon et al. (2018) mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation. J Biol Chem 293:16464-16478
Jian-Yu E; Graber, Judith M; Lu, Shou-En et al. (2018) Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem 25:2595-2607
Perekatt, Ansu O; Shah, Pooja P; Cheung, Shannon et al. (2018) SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium. Cancer Res 78:4878-4890
Zhu, Sining; Jin, Juan; Gokhale, Samantha et al. (2018) Genetic Alterations of TRAF Proteins in Human Cancers. Front Immunol 9:2111

Showing the most recent 10 out of 775 publications